secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K/A
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001193125-23-064669
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation
--------------------------------------------------------------------------------

- Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.
- Severance includes salary continuation for 12 months at his base salary as of separation date.
- Also includes COBRA premium payments until Dec 31, 2023 or earlier if new coverage.
- Compensation Committee awarded 251,296 vested RSUs replacing a canceled option of 199,500 shares for 2021 performance bonus.
- Session also resigned from Board on March 2, 2023, not due to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/d464178d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-064669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer